#USA #Quest Diagnostics #Secaucus #Oropouche Virus #Diagnostics Service

Quest Diagnostics Introduces Testing for Oropouche Virus

On July 15, 2025, Quest Diagnostics (NYSE: DGX), a prominent name in diagnostic information services, announced the rollout of a new diagnostic laboratory test specifically targeting the Oropouche virus. This newly identified virus has been increasingly detected across South and Central America, as well as in the Caribbean regions, raising concerns about its impact on public health.

The Oropouche virus, a pathogen transmitted by infected midges and certain mosquito species, presents a growing challenge for health authorities. Although the current risk remains relatively low for the population in the United States, the virus has seen numerous reported cases throughout its endemic regions. Most of the affected individuals exhibit symptoms similar to those associated with other arboviruses such as Dengue, Zika, and chikungunya. In serious cases, the Oropouche virus can lead to severe neurological complications, including meningitis and encephalitis.

Dr. Yuri Fesko, the Senior Vice President and Chief Medical Officer at Quest Diagnostics, emphasized the crucial role the company plays in enhancing the nation's readiness against emerging infectious diseases like the Oropouche virus. "By developing this test, we are prepared to act quickly to offer scalable testing to complement public health labs should this virus become a public health threat," he stated. This proactive approach underscores the commitment of Quest Diagnostics to safeguarding public health.

The Oropouche virus test will be available by prescription for clinical use starting next month. It will be conducted at Quest's advanced laboratory located in San Juan Capistrano, California. The diagnostic process will initially utilize polymerase chain reaction (PCR) technology, which aids in identifying the RNA of the virus during the early stages of infection. Additionally, serology testing, designed to detect antibodies developed by the body post-infection, will follow within the same quarter. This comprehensive testing strategy ensures that healthcare providers can accurately diagnose Oropouche viral infections, regardless of the infection stage.

A key factor in this initiative is the support provided by the U.S. Centers for Disease Control and Prevention (CDC). In September 2024, Quest Diagnostics was awarded multiple contracts aimed at bolstering testing capacities and laboratory readiness for emerging diseases, which now includes the development of diagnostic measures for the Oropouche virus. These contracts facilitate consistent testing readiness, ensuring that necessary supplies and reagents are in place should any urgent public health response be required.

Quest Diagnostics comments on their broader mission, stating: "We work across the healthcare ecosystem to create a healthier world, one life at a time." By leveraging one of the world’s largest repositories of de-identified clinical lab results, they provide diagnostic insights that empower individuals and healthcare organizations to take meaningful action towards improved health outcomes. With nearly 55,000 dedicated employees, Quest serves approximately one in three adult Americans, playing a pivotal role in the healthcare system.

The introduction of the Oropouche virus test highlights the increasing need for vigilance in response to emerging infectious diseases. As health professionals continue to monitor global health trends, laboratories like Quest Diagnostics are essential in enabling swift responses to safeguard public health across the United States and beyond. For more details about this test and other diagnostic offerings from Quest, visit their official website at www.QuestDiagnostics.com.